SCHEMBL7522157

SCHEMBL7522157

Nc1cccnc1C(=O)N1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.54
PIM3 Q86V86 1/20 0.54
HPGD P15428 5/20 0.46
ALDH1A1 P00352 4/20 0.46
SPR P35270 1/20 0.46
KMT2A Q03164 2/20 0.45
CCR8 P51685 1/20 0.45
KCNH2 Q12809 1/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ADORA2A P29274 1/20 0.43
RIPK1 Q13546 1/20 0.43
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7455826 0.98 PIM1 (0.52) PIM1PIM3HPGDALDH1A1SPR
SCHEMBL7452732 0.95 PIM1 (0.49) PIM1PIM3HPGDALDH1A1SPR
SCHEMBL2140056 0.82 SPR (0.65) PIM1HPGDALDH1A1SPRMAPT
SCHEMBL11204339 0.82 HTT (0.50) HPGDALDH1A1SPRKMT2AMAPT
SCHEMBL22840490 0.82 ACHE (0.51) HPGDALDH1A1KMT2ACCR8KCNH2
SCHEMBL7522153 0.81 NPC1 (0.46) HPGDALDH1A1SPRKMT2AMAPT
SCHEMBL23569884 0.81 PIM1 (0.48) PIM1PIM3HPGDALDH1A1SPR
SCHEMBL9193063 0.80 SPR (0.67) PIM1HPGDALDH1A1SPRKMT2A
SCHEMBL7455823 0.79 PARP1 (0.45) HPGDALDH1A1SPRKMT2AMAPT
SCHEMBL528779 0.79 SPR (0.50) HPGDALDH1A1SPRKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP claimed
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US claimed
US-8623866-B2 2014-01-07 US claimed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 EP claimed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 WO claimed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US claimed
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP disclosed
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US disclosed
US-8623866-B2 2014-01-07 US disclosed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS PDE10A, PDE3A, PDE2A PIM1 4467/4885PIM3 4303/4885HPGD 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.